It is well recognized that IgE plays a central role in. Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma*
|
|
- Virginia Hart
- 5 years ago
- Views:
Transcription
1 Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma* Jean Bousquet, MD; Sally Wenzel, MD, FCCP; Stephen Holgate, MD; William Lumry, MD; Peter Freeman, PhD; and Howard Fox, MD Study objective: To determine baseline characteristics predictive of response to omalizumab, an anti-ige antibody, in patients with allergic asthma. Design: Pooled analysis of two multicenter, double-blind, randomized, placebo-controlled phase III studies with omalizumab. Patients: One thousand seventy allergic asthma patients symptomatic despite moderate-to-high doses (mean, 725 g/d) of inhaled beclomethasone dipropionate (BDP). Interventions: Omalizumab (n 542) or placebo (n 528) were administered at a 4-weekly subcutaneous dose of at least mg/kg/ige (IU/mL) for 16 weeks in addition to stable BDP therapy. Measurements and results: Univariate logistic regression was performed to explore baseline variables predictive of best response. Various aspects of response (reduced symptom scores, reduced usage of rescue medication, improved lung function, improved quality of life [QoL]) were explored as well as a composite definition of response (response in at least one of these four aspects with no asthma exacerbation during 16 weeks of treatment). Time to onset of response as well as the ability to predict eventual response were also determined for the composite definition of response. A consistent pattern of predictive covariates was seen over all definitions of response (except for QoL). For the composite definition, a history of emergency asthma treatment in the past year was the factor most predictive (p 0.015) of best response on active treatment (response rate for those with such history was 67% for omalizumab and 42% for placebo; for those without a history the response rates were 63% and 54%, respectively). Another factor predictive of best response on active treatment was high BDP dose (p 0.037; response rate for those treated with > 800 g/d was 65% for omalizumab and 40% for placebo; for those treated with < 800 g/d, the response rates were 63% and 55%, respectively). A low FEV 1 was also predictive (p 0.072; response rates for those with FEV 1 < 65% predicted were 60% for omalizumab and 40% for placebo; for those with FEV 1 > 65% predicted, the response rates were 67% and 53%, respectively). Seventy-six percent of patients had at least one of these factors. This subgroup showed odds of being a responder (composite definition) 2.25 times higher (95% confidence interval, 1.68 to 3.01) than placebo. Some 38% of patients treated with omalizumab showed a response (composite definition) at the first evaluation time point at 4 weeks, increasing to 64% at week 16 (vs 48% for placebo; p < 0.001). Among omalizumab responders at 16 weeks, only 61% had responded at 4 weeks whereas 87% had responded at 12 weeks. Conclusions: Patients who benefit most when omalizumab is administered as add-on therapy are those receiving high doses of BDP, those with a history of frequent emergency asthma treatment, and those with poor lung function. Patients should be treated with omalizumab for a minimum duration of 12 weeks. (CHEST 2004; 125: ) Key words: allergic asthma; anti-ige antibody; omalizumab Abbreviations: BDP beclomethasone dipropionate; CI confidence interval; ICS inhaled corticosteroids; QoL quality of life; PEF peak expiratory flow It is well recognized that IgE plays a central role in the inflammatory response to allergen exposure in the atopic patient. 1 Specific targeting of IgE with an anti-ige antibody therefore represents a promising new approach to the treatment of allergic asthma and other IgE-mediated inflammatory disorders. 2 Recently, a recombinant humanized monoclonal anti-ige antibody, omalizumab, was developed. This agent binds to the same region of the IgE molecule that interacts with IgE receptors, ie, the C 3 do Clinical Investigations
2 main, 3 thereby inhibiting the allergic cascade by markedly reducing the serum concentration of free IgE. 4 The validity of this approach is supported by the findings of two large placebo-controlled studies 5,6 in patients with allergic asthma who were symptomatic despite moderate-to-high doses of inhaled corticosteroids (ICS). When added to existing therapy, treatment with omalizumab was effective in improving symptom control with parallel reductions in the frequency of exacerbations and requirement for ICS, changes that were clinically meaningful to patients in view of significant improvement in their asthma-related quality of life (QoL). 7,8 With any medical therapy, some patients will experience greater clinical benefit than others, and knowing which patients are likely to achieve the best response aids clinical decision making. The aim of the present exploratory analysis was to determine baseline patient characteristics predictive of the best response to omalizumab therapy for allergic asthma. In addition, we determined the time to onset of response and how long patients need to be treated with omalizumab before a response could be accurately predicted. Materials and Methods The present analysis used data from adults and adolescents (aged 12 years) with allergic asthma, symptomatic despite moderate-to-high daily doses of ICS (beclomethasone dipropionate [BDP]), who were randomized to treatment in two phase III, double-blind, placebo-controlled, multicenter studies. The identical study design and similarities in patient populations and clinical findings justified pooling of the two studies, the protocol *From the Service de Pneumologie (Dr. Bousquet), Hôpital Arnaud de Villeneuve, Montpellier, France; the National Jewish Medical and Research Center (Dr. Wenzel), Denver, CO; Southampton General Hospital (Dr. Holgate), Southampton, UK; the Asthma and Allergy Research Associates (Dr. Lumry), Dallas, TX; and Novartis Horsham Research Centre (Drs. Freeman and Fox), Horsham, UK. This study was supported by Novartis Pharma AG, Basel, Switzerland, and Genentech Inc., South San Francisco, CA. According to their statement, the authors and all study investigators have not made any financial arrangement whereby the value of the compensation could be influenced by the outcomes of the study, have not received significant payments of other sorts from the sponsors (excluding the costs of conducting the study), do not have a proprietary or financial interests in the test product such as patent, trademark, or licensing agreements, and do not hold a significant equity interest in the sponsor of the study (exceeding $50,000). Drs. Freeman and Fox hold permanent positions with Novartis Pharma AG. Manuscript received March 15, 2002; revision accepted July 30, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( permissions@chestnet.org). Correspondence to: Jean Bousquet, MD, Service de Pneumologie, Hôpital Arnaud de Villeneuve, 371 avenue du Doyen G Giraud, Montpellier 34295, France; jean.bousquet@wanadoo.fr and main efficacy findings of which are reported in full elsewhere. 5,6 Briefly, the studies enrolled patients with a diagnosis of asthma of at least 1 year in duration, serum total IgE level of 30 to 700 IU/mL, and a positive, immediate skin-prick test result to at least one common allergen (dust mite, dog or cat [both studies] or cockroach [Busse et al 5 only]). Further inclusion criteria included baseline FEV 1 (without bronchodilators) 40% and 80% of predicted, increasing by 12% within 30 min of receiving an inhaled, short-acting 2 -agonist. Each study was performed in accordance with the latest revisions to the Declaration of Helsinki, with patients (or guardians, where appropriate) providing written informed consent before enrollment. Ethical approval was obtained from the institutional review board of each participating study center. Both studies commenced with a 4- to 6-week run-in and baseline period, during which patients were switched to inhaled BDP and maintained on the lowest dose required to maintain asthma symptoms and lung function at levels acceptable to the patient and investigator. Thereafter, patients were randomized (using a computer-generated scheme) to receive subcutaneous omalizumab or matching placebo every 2 weeks or 4 weeks (at least mg/kg/ige [IU/mL] every 4 weeks) for 16 weeks in addition to stable BDP therapy. Blinding was maintained by the preparation of study medication by nonstudy-related personnel at each center. Concomitant asthma medications (other than BDP and short-acting 2 -agonist [albuterol] as rescue) were not permitted during the study, throughout which patients recorded symptoms of asthma, morning peak expiratory flow (PEF), and usage of rescue bronchodilators in daily diary cards. Asthma symptoms were recorded twice daily; nocturnal symptom assessment included the use of rescue medication, and daytime symptom assessment incorporated limitations in physical activity. Both were assessed using a 4-point scale. Total symptom score was therefore computed as the sum of the daytime and nocturnal scores, plus morning score of 0 no and 1 yes for asthma symptoms on awakening, with a maximum score of 9. No imputation was used for missing diary card (symptom scores) or spirometry data. Asthma-related QoL was evaluated at baseline and on completion of 16 weeks of treatment using the 32-item Juniper Asthma Quality of Life Questionnaire. 9 Each question was answered by the patient on a 7-point scale with 1 representing the greatest impairment and 7 representing no impairment during the past 2 weeks. Lower scores on this questionnaire therefore reflect increased impairment. Items were equally weighted and reported as an overall score. The last observation-carried-forward approach was used for missing asthma-related QoL data. Time to First Asthma Exacerbation Asthma exacerbations were protocol defined as those requiring a doubling of baseline BDP dose or use of systemic steroids. For the 16-week treatment period, we assessed the distribution of time to first exacerbation episode using the Kaplan-Meier (product-limit) method. For the purposes of this analysis, patients who discontinued (prior to their first exacerbation) were assumed to have done so because of an exacerbation. For other patients who were prematurely withdrawn, the number of exacerbations was imputed using the following formula: imputed No. observed No. (No. of days from withdrawal to planned end of phase)/14. An imputation method was applied given that withdrawn patients had different lengths of exposure to risk of exacerbation. Between-group differences for time to first exacerbation episode were analyzed using the nonparametric log-rank test. The use of this test was deemed preferable to an assumption-dependent one, such as Cox analysis, given that nearly 80% of patients were CHEST / 125 / 4/ APRIL,
3 exacerbation free, so all that was known about their time to first exacerbation was that it was 16 weeks. Probability of Response Univariate logistic regression 10 was performed to determine whether baseline covariates (Table 1) were predictive of a greater probability of response on omalizumab compared with placebo. Three terms were included in each regression equation: treatment, baseline covariate, and interaction, which indicated differential prediction of response for the two treatments. Interaction coefficients with a p value 0.2 were considered predictive (covariates significantly predictive of response, ie, p 0.05, were highlighted). This level of probability was chosen in order to encompass covariates that, while being only slightly predictive, could be of potential clinical interest and therefore practically useful. Various a priori-defined aspects of response were explored: (1) reduced symptoms (reduction of 1 in mean total asthma symptom score [range 0 to 9] between baseline and study end [mean over week 12 to week 16] with no increase in mean use of rescue albuterol); (2) reduced usage of rescue medication (reduction of 1 in mean number of puffs of rescue medication per day between baseline and study end with no increase in total symptom score); (3) improved lung function (increase in mean morning PEF of 15% between baseline and study end); and (4) improved QoL (increase of 1.0 in overall score on the Juniper Asthma Quality of Life Questionnaire 9 between baseline and study end). A composite definition of response, defined as response in at least one of these four aspects with no asthma exacerbation during 16 weeks of treatment, was also investigated. Between-group comparisons for equality of percent responders were evaluated using the Cochran-Mantel-Haenszel test. Three severity factors were subsequently identified from the main analysis as important determinants of response: BDP dose, history of emergency asthma treatment in the past year (a composite variable based on history in the last year of at least one of the following events: overnight hospital admission or treatment in an ICUs for asthma; emergency department or doctor s office visit for urgent asthma treatment), and FEV 1. In order to explore the interrelationships between these three factors, BDP was classified as high if 800 g/d and FEV 1 as low if 65% predicted. Each patient was then classified according to how many of these factors he or she possessed, giving four subgroups corresponding to 0, 1, 2, or 3 factors. Within each subgroup, the proportion of patients who responded with either omalizumab or placebo was calculated (p 1 and p 2, respectively). The odds of being a responder was subsequently determined by O 1 p 1 / (1 p 1 ) and O 2 p 2 /(1 p 2 ), giving the odds ratio of O 1 /O An odds ratio of 1 indicated equality of incidence of responders on the two treatments, while a value 1 indicated more responders with active treatment than with placebo. Statistical significance (5% level) was assumed if the lower limit of the 95% confidence interval (CI) for the odds ratio was 1. Specific statistical validation of the logistic regression model used in the present study was not performed. Rather, we relied on the generalized likelihood ratio statistic for testing the goodness of fit of the model, with its associated p value based on the asymptotic 2 distribution. We believed that the sample sizes Characteristics Table 1 Baseline Characteristics* Omalizumab (n 542) Placebo (n 528) Age, yr (range) 39.7 (12 76) 39.0 (12 74) Female/male gender, No. 297/ /238 BDP dose, g/d 724 (500 1,600) 726 (200 2,000) Rescue albuterol use, puffs/d 4.7 (0 14.6) 4.7 (0 18.1) Serum total IgE, IU/mL 198 (20 860) 196 (21 814) Active dermatitis, No. (%) 36 (6.6) 55 (10.5) No. of positive allergens 2.72 (0 5) 2.67 (0 5) Duration of asthma, years 20.5 (1 68) 20.8 (1 63) Total symptom score (0 to 9) 4.11 (0 8.36) 4.14 (0 8.64) Nocturnal symptom score (0 to 4) 1.2 (0 3.7) 1.2 (0 4) Overall QoL score (1 to 7) 4.31 ( ) 4.31 ( ) In the past year: No. of visits to a doctor s office for urgent asthma treatment 0.94 (0 15) 1.01 (0 24) Overnight hospital admission for asthma, No. (%) 17 (3.3) 31 (6.3) No. of emergency department visits for asthma treatment 0.20 (0 12) 0.25 (0 20) Asthma treatment in an ICU, No. (%) 6 (1.1) 5 (0.9) History of any emergency asthma treatment, No. (%) 216 (41.5) 201 (41.4) FEV 1 Absolute value, ml 2,426 (650 5,120) 2,441 (640 5,050) % predicted 69 (30 112) 69 (22 111) 65% predicted, No. (%) 118 (21.8) 112 (21.2) Mean FVC, ml 3,489 (1,370 7,760) 3,481 (380 7,480) Mean FEF 25 75%, ml/s 1,832 (250 6,860) 1,825 (220 4,980) Mean morning PEF, L/min 347 ( ) 354 ( ) *Data are presented as mean (range) unless otherwise indicated. FEF 25 75% forced expiratory flow, midexpiratory phase. Ex-valve. Determined by the Juniper Asthma Quality of Life Questionnaire. 9 A composite variable based on history in the last year of at least one of the following events: overnight hospital admission or treatment in an ICU for asthma, or at least one emergency department or doctor s office visit for urgent asthma treatment Clinical Investigations
4 were sufficient to justify the asymptotics and relied on this statistic for validation of the logistic regression. Colinearity was not a problem. Predicting Eventual Response Substantially the same a priori responder definitions were adopted in order to determine, from a composite perspective, the time to onset of response and how response at 4, 8, and 12 weeks related to eventual response for those completing 16 weeks of treatment and with no asthma exacerbation. The QoL improvement category was omitted, in view of the fact that QoL scores were only determined after 16 weeks of treatment and not at earlier time points. Results The pooled patient population comprised 1,070 adults and adolescents with allergic asthma who were randomized to treatment with either omalizumab (n 542) or placebo (n 528) in addition to stable BDP therapy. Overall, the two treatment groups were comparable in terms of baseline characteristics (Table 1). Completer rates for the 16-week, steroidstable phase were 95.2% (516 of 542 patients) for those treated with omalizumab and 90.7% (479 of 528 patients) for placebo recipients. Time to First Asthma Exacerbation Omalizumab-treated patients had significantly longer times to their first asthma exacerbation than placebo-treated patients (p 0.001). By week 16, the probability of having had an exacerbation episode was 30% for placebo compared with 16% for omalizumab. Probability of Response Overall, response rates with omalizumab were significantly superior to those with placebo (Table 2). In terms of predictive covariates, a consistent pattern was seen over all definitions of response, except for QoL (Table 3; covariates that were significantly predictive [p 0.05] are indicated). For the composite definition, factors predictive of a greater probability of response on active treatment included high BDP dose, history of emergency asthma treatment in the past year, and low FEV 1 (Fig 1). Overall, 742 of 979 patients (76%) had at least one of these three factors. With regard to the composite definition, this subgroup of 742 patients showed odds of being a responder 2.25 times higher (95% CI, 1.68 to 3.01) with omalizumab than with placebo. The odds ratio for the composite definition of response increased with increasing number of concomitant high-severity covariates (Fig 2), a finding that was also apparent across all four individual definitions of response (Table 4). Table 2 Response Rates (After 16 Weeks of Treatment), According to Definition of Response* Response Omalizumab Placebo p Value Reduced symptoms 276/517 (53) 203/481 (42) Reduced usage of 275/517 (53) 189/481 (39) rescue medication Improved lung 107/519 (21) 49/486 (10) function Improved QoL 184/447 (41) 129/414 (31) Composite definition 334/521 (64) 235/488 (48) *Data are presented as No./No. of patients (%) with sufficient data to enable response or nonresponse to be determined. Patients with missing data were excluded. Reduction of 1 in mean total asthma symptom score with no increase in mean use of rescue albuterol. Reduction of 1 in mean number of puffs of rescue medication per day with no increase in total symptom score. Increase in mean morning PEF rate of 15%. Increase in overall score of 1.0 on the Juniper Asthma Quality of Life Questionnaire. 9 Response in at least one of the four response categories with no asthma exacerbation during 16 weeks of treatment. Predicting Eventual Response Further analysis of the composite response rates was completed to determine time to onset of response and how response at 4, 8, and 12 weeks related to eventual response at study end. Many patients receiving omalizumab could be classified as responders at the first analysis time point at 4 weeks, and the proportion of responders continued to increase throughout the 16-week period. In terms of predicting response to omalizumab, 61% of eventual responders at 16 weeks had responded at 4 weeks, increasing to 87% at 12 weeks (Table 5). Discussion Identification of those patients most likely to achieve the greatest benefit from omalizumab therapy has obvious implications for clinical decision making on the utility of this new treatment option for allergic asthma. In the present study, based on the findings of two large placebo-controlled phase III clinical trials, 5,6 a pooled exploratory analysis was therefore performed in an attempt to characterize such patients. Various aspects of response to omalizumab (as add-on therapy to standard care with ICS) were explored relative to placebo, given that asthma affects different patients in different ways. The corresponding definitions of response also took into account the large, and comparable, placebo response observed in the two original studies. 5,6 This placebo effect was particularly apparent in terms of asthmarelated QoL, 7,8 and can probably be explained by CHEST / 125 / 4/ APRIL,
5 Table 3 Summary of Predictive Covariates, According to Definition of Response* Covariates Reduced Symptoms Reduced Usage of Rescue Medication Improved Lung Function Improved QoL Composite Definition Direction of Greatest Benefit with Omalizumab Age 0.16 Older Gender BDP dose Higher Total IgE level 0.20 Higher Active dermatitis No. positive allergens Higher Duration of asthma Total symptom score 0.12 Higher Overall QoL score Lower In the past year: No. of visits to a doctor s office for urgent Higher asthma treatment Overnight hospital admission for asthma Yes Number of emergency department visits for asthma treatment Treatment for asthma in an ICU History of emergency asthma treatment Yes FEV 1 Absolute value Lower % predicted Lower 65% predicted or 65% predicted % FVC Lower FEF 25 75% Lower Morning PEF Lower *Values shown are p values for the significance of the treatment-by-predictive covariate interaction. A small p value means that the graph of probability of response against the value of the baseline covariate gives lines for omalizumab and placebo groups that are very nonparallel. See Table 1 for expansion of abbreviation. Covariates that were significantly predictive of response (p 0.05); absence of stated value indicates p 0.2. For definitions of response, see Table 2. Indicates the trend associated with the greatest benefit from omalizumab relative to placebo, in terms of the composite definition of response. A high total symptom score indicates a patient with severe symptoms. Lower score indicates greater impairment of QoL. A composite variable based on history in the last year of at least one of the following events: overnight hospital admission or treatment in an ICU for asthma, or at least one emergency department or doctor s office visit for urgent asthma treatment. improved compliance with BDP treatment and/or intensive medical input. It is worth noting that steroid dosing in most of these patients was at a level above which a further dose response would be unlikely. Overall, on the basis of extensive clinical information available, it was apparent that the greatest benefit from add-on omalizumab therapy (relative to placebo as add-on to standard care with ICS) was observed for the subgroup of more difficult-to-treat patients, ie, those receiving higher doses of ICS, patients with poor lung function, and those with a history of emergency asthma treatment in the last year. Indeed, patients with any of these factors had more than twice the odds of responding with omalizumab than with placebo. In this respect, it is notable that Holgate et al 12 reported that in patients with allergic asthma at high risk of serious asthmarelated morbidity and mortality, omalizumab offers the potential to halve the rate of asthma exacerbations and improve disease control. Patients were defined as being high risk if they had prior intubation or had visited an emergency department, experienced an overnight hospitalization, or had undergone treatment in an ICUs within the last year. Interestingly, baseline total IgE level was not predictive of response, which can probably be explained by the fact that the reduction in serum free IgE is so pronounced with omalizumab. Indeed, the customized omalizumab dosing strategy that was employed in these studies, a 4-weekly subcutaneous dose of at least mg/kg/ige (IU/mL), was specifically designed to achieve serum free IgE levels 10 IU/mL irrespective of the baseline value. Reference to the findings of both Busse et al 5 and Solèr et al 6 shows that a reduction in serum free IgE levels to below this threshold was successfully achieved in both studies Clinical Investigations
6 Figure 1. Probability of response (composite definition; predicted from logistic regression model) in relation to baseline dose of BDP (top) and baseline FEV 1 (bottom). Treatment with omalizumab allowed a significant reduction in concomitant ICS dosage in the two large placebo-controlled phase III clinical trials 5,6 that formed the basis of the present analysis. The steroid-reduction phase was, of course, reported fully as part of the efficacy analyses of the two studies, but this end point was not investigated as a possible response criterion in the present responder analysis because it only introduced confounding features. Until recently it has not been possible to determine the precise contribution of IgE mechanisms with increasing severity of allergic asthma. In such patients, the involvement of T cells of the T-helper type 2 subtype, which are considered to orchestrate the basophil, mast cell, and eosinophil responses through the release of a variety of cytokines, has been clearly established. 13 What the current analysis clearly shows is that IgE continues to contribute to disease pathogenesis in atopic subjects who have persistent asthma despite treatment with ICS. IgE has been shown to be produced locally in the mucosa of subjects with allergic airways disease, 14 and in vitro studies 15 show that corticosteroids enhance, rather than diminish, IgE production by a direct action on B cells. Thus, while having the ability to suppress T-helper type 2 cytokine production, a downside of repeated high-dose ICS treatment could be the maintenance of an ongoing local IgE response that could be amenable to omalizumab therapy. CHEST / 125 / 4/ APRIL,
7 Figure 2. Venn diagram of odds ratios (corresponding 95% CIs) for response with omalizumab relative to placebo for the composite definition of response, according to three high-severity baseline covariates. As highlighted above, the present study aimed to determine the population of omalizumab-treated patients with best response relative to placebo when administered as add-on therapy to current standard care with ICS. A large placebo response was apparent, in line with the original study findings of Busse et al 5 and Solèr et al. 6 However, Figure 1 shows that this placebo effect occurred predominantly in the less severe patients. In contrast, the probability of response with omalizumab was relatively independent of disease severity, as shown by the near horizontal nature of the plots of probability response (Fig 1). Thus, divergence of the omalizumab and placebo plots of the probability of response was greatest for those with more severe disease. In the case of FEV 1, for example, this meant a higher likelihood of response with active treatment than with placebo for those with the poorest lung function. Table 4 Odds Ratios for Response With Omalizumab vs Placebo After 16 Weeks of Treatment, According to Number of High-Severity Covariates and Definition of Response* A potential criticism of our study, which gives rise to the exploratory nature of its findings, is that we had to assign a priori cut-off points in order to dichotomize outcomes into responders and nonresponders for purposes of predictive analysis. In the case of reduced symptoms, for example, response was assumed if mean total asthma symptom score decreased by 1 point with no additional usage of rescue bronchodilators. This cut-off was chosen because it was considered a meaningful improvement relative to a mean baseline score of 4 to 5. Similarly, a reduction in mean usage of rescue medication of 1 puffs per day, with no increase in total symptom score, was considered clinically meaningful vs mean baseline usage of 4 to 5 puffs per day. Another response category was an improvement in mean morning PEF of 15%. This cut-off was assigned given that only modest improvements in PEF were seen in the original studies. 5,6 Thus, the PEF re- High- Severity Covariates, No. Reduced Symptoms Reduced Usage of Rescue Medication Improved Lung Function Improved QoL Composite Definition No. OR (95% CI) No. OR (95% CI) No. OR (95% CI) No. OR (95% CI) No. OR (95% CI) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) *OR odds ratio. For definitions of response, see Table 2. BDP dose 800 g/d and/or history of emergency asthma treatment in the past year and/or FEV 1 65% predicted Clinical Investigations
8 Table 5 Prediction of Eventual Response (Composite Definition)* False-Positive False-Negative Sensitivity Specificity Time Points Omalizumab Placebo Omalizumab Placebo Omalizumab Placebo Omalizumab Placebo Week 4 8 (16/206) 18 (23/130) 38 (120/314) 29 (104/356) 61 (190/310) 51 (107/211) 92 (194/210) 92 (252/275) Week 8 11 (29/272) 15 (27/176) 27 (67/248) 20 (63/310) 78 (243/310) 70 (149/212) 86 (181/210) 90 (247/274) Week (32/303) 13 (27/206) 18 (39/217) 12 (33/280) 87 (271/310) 84 (179/212) 85 (178/210) 90 (247/274) *Data are presented as % (No./total patients). Percentage of patients responding who did not respond at 16 weeks. Percentage of patients not responding who became responders at 16 weeks. Percentage of patients who were responders at 16 weeks and had achieved response at the respective time point. Percentage of patients who were not responders at 16 weeks who were not responders at 4 weeks. sponse threshold was set at a level that was low enough to identify patients who did show some response, but was sufficiently high enough to be considered a meaningful improvement for those who had at least moderate impairment of their baseline lung function. Finally, we considered response in terms of asthma-related QoL improvement, identifying responders as those patients whose overall score on the Juniper Asthma Quality of Life Questionnaire increased by 1.0 point. This threshold is higher than the minimal important change of 0.5 points identified by Juniper and colleagues. 16 However, because of the large placebo effect in both studies, 7,8 the proportion of responders in both groups was believed to be too high to be informative if the latter definition of QoL improvement was used. The differentiation between groups was likely to become more apparent when we required a larger improvement in QoL. We therefore adopted a cutoff for response of an improvement in score of 1.0 point, which is consistent with a moderate improvement of QoL according to Juniper and colleagues. 16 Overall, however, while the present analysis was exploratory in nature and therefore hypothesis generating, the fact that the results are so consistent and hang together clinically as well as statistically encourages us to believe that they are reliable and replicable. The (composite) response to omalizumab was clearly characterized by a progressive onset, with 38% of patients responding within 4 weeks of starting treatment, increasing to 64% at week 16. Overall, a low percentage of patients responding at early time points failed to respond at 16 weeks, indicating that in most cases response to omalizumab is durable. An important finding was that only 61% of patients who were responders at 16 weeks had responded at 4 weeks, increasing to 87% at 12 weeks. Such findings indicate that it would be inadvisable to treat patients for a minimum of 4 weeks and then discontinue treatment if response was not observed, as at least one third of all eventual responders would be potentially missed using this strategy. In contrast, only 18% would be missed at 12 weeks. These findings support a minimum treatment duration of 12 weeks of add-on therapy with omalizumab before deciding whether to continue therapy. Conclusion Treatment with omalizumab significantly reduces the risk of asthma exacerbations in patients with allergic asthma. Asthma patients who benefit most from add-on treatment with omalizumab are those receiving high doses of ICS, those with a history of frequent emergency asthma treatment, and patients with poor lung function. A minimum treatment duration of 12 weeks appears necessary before deciding whether a satisfactory response will be achieved with omalizumab. Taken together, these findings will aid the clinical decision of whether a patient is likely to benefit from receiving omalizumab in addition to standard therapy for allergic asthma. References 1 Spector SL. Allergic inflammation in upper and lower airways. Ann Allergy Asthma Immunol 1999; 83: Jardieu PM, Fick RB Jr. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999; 118: Presta L, Shields R, O Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269: Milgrom H, Fick RB, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-ige antibody. N Engl J Med 1999; 341: Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-ige recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: Solèr M, Matz J, Townley R, et al. The anti-ige antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: Buhl R, Hanf G, Solèr M, et al. The anti-ige antibody omalizumab improves asthma-related quality of life in pa- CHEST / 125 / 4/ APRIL,
9 tients with allergic asthma. Eur Respir J 2002; 20: Kishiyama JL, Lainer BQ, Corren J, et al. rhumab-25 (E25) improves asthma-specific quality of life in patients with allergic asthma [abstract]. Allergy Clin Immunol Int 2000; 105 (Suppl 2):115 9 Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: Agresti A. Analysis of ordinal categorical data. New York, NY: John Wiley and Sons, Agresti A. Categorical data analysis. New York, NY: John Wiley and Sons, Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: Cameron L, Hamid Q. Regulation of allergic airways inflammation by cytokines and glucocorticoids. Curr Allergy Asthma Rep 2001; 1: Durham SR, Gould HJ, Thienes CP, et al. Expression of epsilon germ-line gene transcripts and mrna for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. Eur J Immunol 1997; 27: Jabara HH, Ahern DJ, Vercelli D, et al. Hydrocortisone and IL-4 induce IgE isotype switching in human B cells. J Immunol 1991; 147: Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: Clinical Investigations
Predicting and evaluating response to omalizumab in patients with severe allergic asthma
Respiratory Medicine (2007) 101, 1483 1492 Predicting and evaluating response to omalizumab in patients with severe allergic asthma J. Bousquet a,, K. Rabe b, M. Humbert c, K.F. Chung d, W. Berger e,h.fox
More informationOmalizumab improves asthma-related quality of life in patients with severe allergic asthma
Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MD, a Gary Gross, MD, b Julius van Bavel, MD, c Theodore Lee, MD, d Hugh Windom, MD, e François Everhard,
More informationThe anti-ige antibody omalizumab improves asthma-related quality of life in patients with allergic asthma
Eur Respir J 22; 2: 188 194 DOI: 1.1183/931936.2.1652 Printed in UK all rights reserved Copyright #ERS Journals Ltd 22 European Respiratory Journal ISSN 93-1936 The anti-ige antibody omalizumab improves
More informationAnti-IgE for chronic asthma in adults and children (Review)
Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2007, Issue 4
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationTargeted IgE Therapy for Patients With Moderate to Severe Asthma
Targeted IgE Therapy for Patients With Moderate to Severe Asthma Bradley E. Chipps, MD Medical Director, Capital Allergy and Respiratory Disease Center, Sacramento, Calif. Patricia L. Marshik, PharmD Assistant
More informationPharmacy Medical Policy IgE Receptor Binding Inhibitors
Pharmacy Medical Policy IgE Receptor Binding Inhibitors Table of Contents Policy: Commercial Policy History Endnotes Policy: Medicare Information Pertaining to All Policies Forms Coding Information References
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationSUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationThe Appropriate Omalizumab Patient Management of the uncontrolled asthma patient and case examples
The Appropriate Patient Management of the uncontrolled asthma patient and case examples Jill Karpel, MD, Donald A. Bukstein, MD,* Robert LoNigro, MD Beth Thalheim Asthma Center, North Shore University
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationAllergic asthma and seasonal allergic
Novel Treatment of Allergic Asthma and Seasonal Allergic Rhinitis: Focus on Omalizumab (Xolair ) Boris Nogid, PharmD, and Timothy S. McCall, RPh Allergic asthma and seasonal allergic rhinitis (SAR) are
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationomalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd.
Scottish Medicines Consortium Re-Submission omalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd. 8 December 2006 The Scottish Medicines Consortium (SMC)
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationAchieving guideline-based asthma control: does the patient benefit?
Eur Respir J ; : 88 9 DOI:.8/99..97 Printed in UK all rights reserved Copyright #ERS Journals Ltd European Respiratory Journal ISSN 9-9 Achieving guideline-based asthma control: does the patient benefit?
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationA comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma
Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires
More informationXolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.
Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next
More informationTreatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab) Henry Milgrom, MD*; William Berger, MD ; Anjuli Nayak, MD ; Niroo Gupta, MD ; Stephen Pollard, MD ; Margaret McAlary ; Angel
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationOmalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany
Respiratory Medicine (2009) 103, 1725e1731 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Omalizumab in patients with severe persistent allergic asthma in a real-life
More informationOmalizumab for Asthma
clinical therapeutics Omalizumab for Asthma Robert C. Strunk, M.D., and Gordon R. Bloomberg, M.D. This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion
More informationOmalizumab: the evidence for its place in the treatment of allergic asthma
Place in therapy review Omalizumab: the evidence for its place in the treatment of allergic asthma Diarmuid M. McNicholl, Liam G. Heaney Regional Respiratory Centre, Belfast City Hospital, Belfast, UK
More informationClinical Study Report SLO-AD-1 Final Version DATE: 09 December 2013
1. Clinical Study Report RANDOMIZED, OPEN, PARALLEL GROUP, PHASE IIIB STUDY ON THE EVALUATION OF EFFICACY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY IN PAEDIATRIC PATIENTS WITH ATOPIC DERMATITIS, WITH OR WITHOUT
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationDaclizumab improves asthma control in patients with moderate to. severe persistent asthma: A randomized, controlled trial
Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial William W. Busse, MD, Elliot Israel, MD, Harold S. Nelson, MD, James W. Baker, MD,
More informationOmalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Eur Respir J 2002; 20: 73 78 DOI: 10.1183/09031936.02.00278102 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Omalizumab provides long-term
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationAsthma and Vocal Cord Dysfunction
Asthma and Vocal Cord Dysfunction Amy L. Marks DO, FACOP Pediatric Allergy and Immunology Assistant Professor of Pediatrics Oakland University William Beaumont School of Medicine Objectives: Understanding
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationThe anti-ige antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Eur Respir J 2001; 18: 254 261 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 The anti-ige antibody omalizumab reduces exacerbations and
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationAsthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
More informationE-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling
E-1 Role of IgE and IgE receptors in allergic airway inflammation and remodeling Ruby Pawankar, MD, Ph.D. FRCP, FAAAAI Prof. Div of Allergy, Dept of Pediatrics Nippon Medical School Tokyo, Japan pawankar.ruby@gmail.com
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationCost-effectiveness of omalizumab in patients with severe persistent allergic asthma Brown R, Turk F, Dale P, Bousquet J
Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma Brown R, Turk F, Dale P, Bousquet J Record Status This is a critical abstract of an economic evaluation that meets the
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationIdentification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program
Moore online supp 1 Online Data Supplement Identification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program Wendy C. Moore, MD, Deborah A. Meyers, PhD, Sally E. Wenzel,
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationAllergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 75 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 75: Approach to Infants and Children with Asthma
More informationTreatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology
Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the
More informationW e have shown in a previous meta-analysis of placebo
16 ASTHMA Clinical dose-response relationship of fluticasone propionate in adults with asthma M Masoli, M Weatherall, S Holt, R Beasley... See end of article for authors affiliations... Correspondence
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationAdd on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes
Add on therapy in asthma Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes Programme Omalizumab Evidence and assessment Local Experience Dysfunctional breathing The other effective
More informationMepolizumab (asthma)
IQWiG Reports Commission No. A16-33 Mepolizumab (asthma) Addendum to Commission A16-03 1 Addendum Commission:A16-33 Version: 1.0 Status: 29 June 2016 1 Translation of addendum A16-33 Mepolizumab (Asthma)
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationSHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2
SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationOmalizumab for asthma in adults and children(review)
Cochrane Database of Systematic Reviews Omalizumab for asthma in adults and children(review) NormansellR,WalkerS,MilanSJ,WaltersEH,NairP NormansellR,WalkerS,MilanSJ,WaltersEH,NairP. Omalizumab for asthma
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationImmunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012
Drug, Treatment, Device name Omalizumab (Xolair; Novartis) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012 Licensed indication Omalizumab
More informationT he use of inhaled corticosteroids to control the inflammatory
791 ORIGINAL ARTICLE Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose D Price, D Dutchman, A Mawson, B Bodalia, S Duggan, P Todd on behalf of the
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationEvidence Review Group report. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years
Evidence Review Group report Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years Produced by Centre for Reviews and Dissemination (CRD) / Centre for Health
More informationOriginal Research Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort
Original Research Omalizumab Treatment for Severe Atopic Asthma in a Real World Montréal Cohort David Haile-Meskale 1, Ron Olivenstein, MD 2,3, Toby Mcgovern, PhD 3, Cathy Fugere 3, James G. Martin, MD
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationMEDICAL POLICY I. POLICY. POLICY TITLE POLICY NUMBER OMALIZUMAB (XOLAIR ) MP-2.123
Original Issue Date (Created): May 3, 2004 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY. Note: Initial Authorization If the patient has been maintained
More informationBronchial Thermoplasty
Bronchial Thermoplasty Policy Number: 7.01.127 Last Review: 9/2014 Origination: 11/2010 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for bronchial
More informationSEVERE ASTHMA - EVIDENCE TABLES APPENDIX 1
Section 2: Biomarkers Biomarkers to predict response to biologic therapies and macrolides Summary of randomized controlled trials Cut-offs Cut-off selection Study Design N Drug Predictive ability to identify
More informationAnti-IgE: beyond asthma
Anti-IgE: beyond asthma Yehia El-Gamal, MD, PhD, FAAAAI Professor of Pediatrics Pediatric Allergy and Immunology Unit Children s Hospital, Ain Shams University Member, WAO Board of Directors Disclosure
More informationPathology of Asthma Epidemiology
Asthma A Presentation on Asthma Management and Prevention What Is Asthma? A chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Nighttime or early morning coughing Pathology
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationFOR PUBLIC CONSULTATION ONLY. Evidence Review: Temperature-controlled laminar airflow device for persistent allergic asthma (children)
Evidence Review: Temperature-controlled laminar airflow device for persistent allergic asthma (children) NHS England Evidence Review: Temperature-controlled laminar airflow device for persistent allergic
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationMontelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial
Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial by Vikram Kumar, a P. Ramesh, a Rakesh Lodha, a R. M. Pandey,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1833/5/06 ASTRAZENECA v GLAXOSMITHKLINE CONCEPT study leavepiece AstraZeneca complained that a leavepiece issued by Allen & Hanburys, part of GlaxoSmithKline, did not present a fair and balanced
More informationTRANSPARENCY COMMITTEE OPINION. 13 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 January 2010 XOLAIR 150 mg, powder and solvent for solution for injection Box containing 1 x 150 mg vial + 1 x
More informationPractical Course Allergen Immunotherapy (AIT) How to be effective. Michel Dracoulakis HSPE- FMO São Paulo-SP Brazil
Practical Course Allergen Immunotherapy (AIT) How to be effective Michel Dracoulakis HSPE- FMO São Paulo-SP Brazil Allergen immunotherapy - beginning Dunbar almost died with first inoculation 1911 Noon
More informationWorld Journal of Pharmaceutical and Life Sciences WJPLS
wjpls, 2018, Vol. 4, Issue 10, 01-08 Research Article ISSN 2454-2229 Firas et al. WJPLS www.wjpls.org SJIF Impact Factor: 5.088 ASTHMA CONTROL Dr. Yaarub Madhloom Abbas 1, Dr. Firas Raad Shihab* 2 and
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationClinical Trial Report Synopsis
This document has been do\vnloaded from \v ww.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More information